Gynaecological Cancers: Biology and Therapeutics

by Sean Kehoe, Richard J. Edmondson, Martin Gore, Iain A. McNeish

Overview

Gynaecological cancers are categorised as 'rare' diseases, although collectively they affect over 16,000 women each year in the UK alone. There is a lack of real understanding of these conditions compared with other malignancies, possibly owing to their relative rarity when viewed as individual diseases. The 60th RCOG Study Group brought together a range of experts to examine as many biological aspects of gynaecological cancers as possible, including both surgical and non-surgical therapies. This book presents the findings of the Study Group, with contents including: • current understanding of the biology of gynaecological cancers • translation of biology to the clinic • state of the art in imaging and therapy • current clinical trials • advances in multimodal therapy • individualised treatment.

Product Details

ISBN-13:	9781906985448
Publisher:	Royal College of Obstetricians and Gynaecologists (RCOG)
Publication date:	06/01/2011
Series:	Royal College of Obstetricians and Gynaecologists Study Group
Pages:	272
Product dimensions:	6.10(w) x 9.13(h) x 0.51(d)

About the Author

Sean Kehoe works as a Consultant at Churchill Hospital and John Radcliffe Hospital, Oxford. He currently serves on the RCOG Council (as Fellows' Representative South East).

Richard J. Edmondson is a Consultant at Queen Elizabeth Hospital, Gateshead.

Martin Gore is Medical Director of The Royal Marsden and Professor of Cancer Medicine at The Institute of Cancer Research.

Iain A. McNeish is a cancer specialist at Barts and the London School of Medicine, part of the Barts Cancer Research UK Centre. He is Deputy Director of the Barts Experimental Cancer Medicine Centre.

Table of Contents

Part I. Biology of Gynaecological Cancers: Our Current Understanding: 1. Morphological sub-types of ovarian carcinoma: new developments and pathogenesis W. Glenn McCluggage; 2. Novel treatment strategies for targeting genetic changes in endometrial cancer Susana Banerjee; 3. Epigenetic biomarkers in ovarian cancer Robert Brown and Janet Graham; 4. Predictive biology of ovarian cancer Christine A. Parkinson and James D. Brenton; Part II. The Translation of Biology to the Clinic: 5. Biology of BRCA1 and BRCA2 genes and implications for cancer management Timothy A. Yap, Yvette Drew and Susan Shanley; 6. Implications of homologous recombination defectiveness in ovarian cancer Richard J. Edmondson, Asima Mukhopadhyay, Aiste Cerbinskaite and Nicola J. Curtin; 7. The future of PARP inhibitors in the treatment of cancer Yvette Drew, Timothy A. Yap and Stan B. Kaye; Part III. Imaging and Therapy: State of the Art: 8. The role of robotics and the future Tim Mould; 9. 'Ultra-radical' surgery in advanced ovarian cancer Oliver Zivanovic and Dennis S. Chi; 10. Antivascular therapy in gynaecological cancers Leena Mukherjee and Gordon Rustin; 11. Oncolytic viral gene therapy in ovarian cancer Iain A. McNeish; 12. Endometrial cancer: what have the clinical trials taught us? Andrew Clamp; 13. Targeting therapies in cancer: opportunities in ovarian cancer Ahmed Ashour Ahmed, Stefan Knapp, Anil K. Sood and Robert C. Bast Jr; 14. Functional imaging: from tumour biology to the clinic Nandita M. deSouza, Evis Sala, Stavroula Kyriazi and Andrea Rockall; Part IV. What Questions Are Being Asked by Current Clinical Trials?: 15. Current clinical trials in ovarian cancer Christina Fotopoulou, Angus McIndoe, Jalid Sehouli and Hani Gabra; 16. Clinical trials in cervical cancer Karen Tipples and Melanie Powell; 17. Clinical trials in vulval cancer Tito Lopes; Part V. Consensus Views: 18. Consensus views arising from the 60th Study Group: Gynaecological Cancers: Biology and Therapeutics; Index.